4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates

Group 1: Earnings Performance - 4D Molecular Therapeutics reported a quarterly loss of $0.79 per share, which was worse than the Zacks Consensus Estimate of a loss of $0.67, and compared to a loss of $0.24 per share a year ago, indicating a significant decline [1] - The company posted zero revenues for the quarter ended September 2024, missing the Zacks Consensus Estimate by 99.76%, compared to revenues of $20.2 million in the same quarter last year [2] - Over the last four quarters, the company has surpassed consensus EPS estimates two times, but has not been able to beat consensus revenue estimates [2] Group 2: Stock Performance and Outlook - 4D Molecular Therapeutics shares have lost approximately 61.2% since the beginning of the year, while the S&P 500 has gained 25.5% [3] - The current consensus EPS estimate for the coming quarter is -$0.70 on $3.7 million in revenues, and for the current fiscal year, it is -$2.74 on $5.11 million in revenues [7] - The estimate revisions trend for 4D Molecular Therapeutics is mixed, resulting in a Zacks Rank 3 (Hold) for the stock, indicating expected performance in line with the market in the near future [6] Group 3: Industry Context - The Medical - Drugs industry, to which 4D Molecular Therapeutics belongs, is currently in the top 25% of over 250 Zacks industries, suggesting a favorable outlook compared to lower-ranked industries [8] - Another company in the same industry, Cosmos Health Inc., is expected to report a quarterly loss of $0.11 per share, representing a year-over-year change of -22.2%, with revenues expected to be $14 million, up 9.2% from the year-ago quarter [9]